Hepatocellular carcinoma (HCC) is the most primary liver cancer. It is one of the most common and deadly cancer worldwide, especially in East Asia. Advanced HCC patients expect a significantly low 5-year survival rate as ...
Apr 18, 2022
0
2
Scientists at UCL have significantly boosted the effectiveness of a therapeutic vaccine designed to control chronic hepatitis B (HBV) infection, after uncovering and thwarting 'the enemy within'.
Apr 13, 2022
0
62
Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified. A drug used ...
Apr 11, 2022
0
21
A new paper in Nature Communications reveals new insights into adaptations made by cancer cells to rewire their metabolism to achieve growth and survive. Among the discoveries include a challenge to a well-known feature in ...
Mar 23, 2022
0
8
Researchers are set to test a non-invasive treatment for inoperable early-stage liver cancer, with a new clinical trial to commence this year across Australia.
Feb 24, 2022
0
3
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for melanoma and other skin cancers, according to research published today in JAMA Dermatology.
Feb 23, 2022
0
1
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, remains a deadly cancer with an incidence that has tripled in the United States since 1980. Individuals with HCC often present at an intermediate ...
Feb 22, 2022
0
2
A cancer pill, preferably without severe side effects, is something we'd all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves ...
Feb 22, 2022
0
2
Each year in the United States, nearly 50,000 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive breast condition that cannot spread. New research published by Wiley online in Cancer, a peer-reviewed ...
Feb 22, 2022
0
3
(HealthDay)—For patients with recurrent cervical cancer after first-line platinum-containing chemotherapy, survival is significantly longer with cemiplimab than with single-agent chemotherapy, according to a study published ...
Feb 11, 2022
0
1
